| scholarly article | Q13442814 |
| P356 | DOI | 10.1183/09031936.00023907 |
| P698 | PubMed publication ID | 17504798 |
| P2093 | author name string | P Jones | |
| K Viel | |||
| G C Donaldson | |||
| S Kesten | |||
| J A Wedzicha | |||
| T M A Wilkinson | |||
| D J Powrie | |||
| K Scrine | |||
| P433 | issue | 3 | |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| sputum | Q259346 | ||
| P304 | page(s) | 472-478 | |
| P577 | publication date | 2007-05-15 | |
| P1433 | published in | European Respiratory Journal | Q12257435 |
| P1476 | title | Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD | |
| P478 | volume | 30 |
| Q36958848 | Autocrine Acetylcholine, Induced by IL-17A via NFκB and ERK1/2 Pathway Activation, Promotes MUC5AC and IL-8 Synthesis in Bronchial Epithelial Cells |
| Q38817408 | Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones |
| Q28391808 | Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting? |
| Q26823339 | Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease |
| Q38690660 | Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis |
| Q39399389 | Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis |
| Q43269192 | Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence |
| Q33698524 | Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis |
| Q46333189 | Dual PDE 3/4 inhibition: a novel approach to airway disease? |
| Q26750751 | Effect of tiotropium on COPD exacerbations: A systematic review |
| Q42913473 | Effects of formoterol and ipratropium bromide on repeated cadmium inhalation-induced pulmonary inflammation and emphysema in rats |
| Q37785279 | Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease |
| Q37207272 | Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude |
| Q43179889 | Impact of efficacy and mortality studies (TORCH and UPLIFT) in bronchodilator treatment of chronic obstructive pulmonary disease |
| Q36859393 | Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium |
| Q47107761 | Inhaled bronchodilators and acute myocardial infarction: a nested case-control study. |
| Q37471085 | Inhaled tiotropium bromide and risk of stroke |
| Q34638204 | Inhibition of granulocyte migration by tiotropium bromide |
| Q37199668 | Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies |
| Q36421017 | Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population |
| Q24197853 | Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis |
| Q40706819 | Long-term outcomes in chronic obstructive pulmonary disease patients: exploring the effects of inhalatory devices and their influence on the outcome |
| Q90429243 | Long-term safety of bilateral targeted lung denervation in patients with COPD |
| Q36464104 | Maternal smoking promotes chronic obstructive lung disease in the offspring as adults |
| Q39102942 | Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation |
| Q39386571 | Optimizing bronchodilation in the prevention of COPD exacerbations |
| Q28070274 | Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review |
| Q37864538 | Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis |
| Q37724621 | Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium |
| Q28596774 | Prevention of COPD exacerbations: medications and other controversies |
| Q39292087 | Reduced COPD exacerbation risk correlates with improved FEV1: A meta-regression analysis. |
| Q37115876 | Safety, tolerability and risk benefit analysis of tiotropium in COPD. |
| Q93150096 | Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial |
| Q33592946 | Sputum myeloperoxidase in chronic obstructive pulmonary disease. |
| Q55005612 | Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. |
| Q37168340 | Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations |
| Q35268308 | Suppression of IL-8 production from airway cells by tiotropium bromide in vitro |
| Q37115916 | Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro |
| Q60047627 | The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD |
| Q41762598 | The effect of tiotropium therapy on markers of elastin degradation in COPD. |
| Q36438669 | The role of bronchodilator treatment in the prevention of exacerbations of COPD. |
| Q26780553 | Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma |
| Q37474538 | Tiotropium HandiHaler in the treatment of COPD: a safety review |
| Q30620671 | Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis |
| Q38258538 | Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease |
| Q41276617 | Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction. |
| Q37973132 | Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease |
| Q43124360 | Tiotropium bromide: an update |
| Q24246991 | Tiotropium for stable chronic obstructive pulmonary disease |
| Q39137733 | Tiotropium formulations and safety: a network meta-analysis |
| Q98163525 | Tiotropium in chronic obstructive pulmonary disease - a review of clinical development |
| Q92577719 | Tiotropium inhibits proinflammatory microparticle generation by human bronchial and endothelial cells |
| Q35153689 | Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials |
| Q24194833 | Tiotropium versus placebo for chronic obstructive pulmonary disease |
| Q24202175 | Tiotropium versus placebo for chronic obstructive pulmonary disease |
| Q42425427 | Tiotropium; more knowledge leads to more questions. |
| Q27015685 | Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review |
Search more.